IPO Update: Gottlieb’s Resignation Pulls Down Five Of Eight Newly Public Biopharmas
There have been eight US biopharma IPOs in 2019, but only three are trading above their launch price – a big change from just three days ago.
You may also be interested in...
Privately held biotech plans to move insulin sensitizer into Phase III with ambitious goals of obtaining accelerated approval based on liver histology, while also trying to show long-term cardiovascular benefits.
Private Company Edition: Nkarta, Passage Bio and Achilles kicked off September with VC deals totaling more than $100m each. Also, Repare raised $82.5m and SutroVax won CARB-X cash.
Commissioner Scott Gottlieb will leave FDA less than two years after his confirmation, but will exit with a substantial list of accomplishments for industry and patients.